Onsdag 7 Januari | 07:10:47 Europe / Stockholm

Kalender

Est. tid*
2027-02-24 08:00 Bokslutskommuniké 2026
2026-10-28 11:20 Kvartalsrapport 2026-Q3
2026-08-26 11:20 Kvartalsrapport 2026-Q2
2026-05-20 N/A Årsstämma
2026-04-29 11:20 Kvartalsrapport 2026-Q1
2026-02-25 08:00 Bokslutskommuniké 2025
2025-12-04 - Extra Bolagsstämma 2025
2025-10-29 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-05-21 - X-dag ordinarie utdelning INIFY 0.00 NOK
2025-05-20 - Årsstämma
2025-04-30 - Kvartalsrapport 2025-Q1
2025-02-26 - Bokslutskommuniké 2024
2024-12-06 - Extra Bolagsstämma 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning INIFY 0.00 NOK
2024-05-14 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning INIFY 0.00 NOK
2023-05-16 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-30 - Extra Bolagsstämma 2022
2022-08-17 - Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Inify Laboratories tillhandahåller cancerdiagnostik genom laboratorietjänster inom patologi. Bolaget använder ett digitalt, standardiserat arbetsflöde för svarstider och kvalitetssäkring, initialt inom prostata diagnostik. Kunderna består främst utav laboratorier och sjukhus. Inify Laboratories grundades 2022 och har sitt huvudkontor i Stockholm, Sverige.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-19 13:18:44
STOCKHOLM - 19 December 2025 - Reference is made to the stock exchange
announcement made by Inify Laboratories AB (publ) (the "Company") on 9 December
2025 regarding the fully guaranteed private placement of new shares in the
Company (the "Private Placement Shares") with gross proceeds of approximately
NOK 92 million with a minimum subscription per subscriber of the NOK equivalent
of EUR 100,000, directed pro-rata towards existing shareholders holding more
than 1,000,000 shares in the Company (the "Private Placement"), and the fully
guaranteed repair issue of approximately NOK 8 million (the "Repair Issue"),
directed pro-rata towards existing shareholders that did not participate in the
Private Placement and who hold less than 1,000,000 shares in the Company. The
offer price per share in both the Private Placement and the Repair Issue is NOK
3.50 (the "Offer Price"). Further, reference is made to the stock exchange
announcement made by the Company on 17 December 2025 regarding the preliminary
results of the Private Placement.

The application period for the Private Placement expired on 16 December 2025 at
16:30 hours (CET). At the expiry of the application period, the Company had
received valid applications for, and has allocated, a total of 25,759,315
Private Placement Shares.  The remaining 507,551 Private Placement Shares in the
Private Placement have been allocated to the guarantors Monsun AS and Auris AS
as follows: (i) Monsun AS: 435,043 Private Placement Shares